NellOne Therapeutics

NellOne is a young biopharmaceutical firm utilizing a skilled protein to carve out a fresh vision for regenerative medicine. This protein, NELL-1 [Neural EGF-Like-Like molecule], is a naturally occurring human protein that induces various processes for tissue growth and development during and after injuries. NellOne Therapeutics, Inc. holds numerous patents in eight different nations and is working on therapies with partners across various modalities to harness the therapeutic potential of NELL-1. Neon Therapeutics is at the forefront of neoantigen-targeted therapies, committed to revolutionizing cancer treatment by guiding the immune system toward neoantigens. Genetic mutations, a characteristic of cancer, can produce specific immune targets known as neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer treatment. We believe that by directing the immune system toward these targets, our neoantigen-targeted therapies will provide a new level of specificity for patients and tumors in the field of cancer immunotherapy.